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LOV domains act as biomolecular sensors for light, oxygen or
the environment’s redox potential. Conformational changes
upon the formation of a covalent cysteinyl flavin adduct are
propagated through hydrogen-bonding networks in the core
of designed hybrid phototropin LOV2 domains that incorpo-
rate the Bcl homology region 3 (BH3) of the key pro-apoptotic
protein BH3-interacting-domain death agonist (BID). The result-
ing change in conformation of a flanking amphiphilic a-helix
creates a light-dependent optogenetic tool for the modulation
of interactions with the anti-apoptotic B-cell leukaemia-2 (Bcl-
2) family member Bcl-xL.
Light-oxygen-voltage (LOV) domains are molecular switches
that act as internal sensors of oxygen, redox potential and
light in cells.[1–3] Some LOV domains function as reversible pho-
toswitches[4] and underpin a range of blue-light responses in
plants, fungi and bacteria including phototropism[5, 6] and regu-
lation of the circadian rhythm.[7] LOV photosensors share
a common mechanism by which a noncovalently bound flavin
cofactor absorbs blue light (450–475 nm) to enter an excited
electronic state; this leads to the formation of a covalent
adduct between flavin mononucleotide (FMN) and the sulfur
atom of a cysteine residue,[8] and significant conformational
changes occur.[9] The FMN adduct spontaneously reverts to its
noncovalently bonded dark state with rates that reflect the
function of the individual LOV domain. Phototropin was one of
the first blue-light receptors discovered in plants, and LOV2
from Avena sativa (AsLOV2) has previously been used for pho-
toprotein engineering. In its dark form, the C-terminal Ja helix
of AsLOV2 is tightly bound to the b-sheet (Figure 1), but upon
light-activated adduct formation, the 20 residues of the C-ter-
minal Ja helix are displaced from the b-sheet, thereby expos-
ing the amphiphilic helix (Figure 2).[10–12] LOV domains have been used to create light-responsive
DNA-binding motifs[13–15] and transcriptional activators,[16,17] as
well as to control the activity of enzymes[18,19] and the subcellu-
lar location[20] and degradation rates[21] of proteins by domain
fusion or insertion. We have previously modified peptide se-
quences from proapoptotic proteins with azobenzene cross-
linkers to create biomolecular nanoswitches (BNs), whose con-
formations and binding properties change in response to
light.[22–24] A LOV-derived protein of equivalent functionality
could be genetically encoded and photoactivated in vivo
through transient expression or gene integration. A LOV/cas-
pase 7 hybrid has previously been shown to cause cell death;
however, overexpression of Bcl-2, which is common in many
types of cancer cells, diminished its proapoptotic effect.[25]
Figure 1. Overall structure of Avena sativa Phototropin 1 LOV2 domain (PDB
ID: 2V1A)[12] with the Ja helix in green.
Figure 2. Cartoon illustrating the dark and irradiated forms of AsLOV2 and
the four hybrids between AsLOV2 and BID, LOV-BID1 to LOV-BID4, with dif-
ferent locations of the BH3 recognition element of BID (red) within the Ja
helix of AsLOV2 (green).
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Previous work has sought to maximise the dynamic range
between the light- and dark-state affinities of LOV–peptide fu-
sions,[21, 26] but controlling potentially irreversible apoptotic pro-
cesses with an expressed protein requires stringent “caging” of
the active epitope. Caging efficiency is affected by the position
of the binding epitope in the Ja helix ; residues incorporated
closer to the body of the protein are better caged in the dark
state but pay a steric penalty in the light state. Well-character-
ised protein–protein interaction motifs have been introduced
into LOV domains to generate generic photoassocia-
tion tools. Incorporating an amino acid sequence
that is strongly bound by PSD-95/discs large/zona oc-
cludens 1 (PDZ) domains into sites between residues
540 and 545 of the Ja helix of AsLOV2 (Table S1) led
to proteins with increased affinities for PDZ in the
light-activated state.[27] Introducing the recognition
sequence at residue 542 led to the widest dynamic
range between dark- and light-state affinities. A pro-
tein database search revealed that peptide sequences
similar to AsLOV2 Ja have been crystallised bound to
interacting partners.[28] Elements of one such se-
quence, the SsrA peptide, were incorporated at resi-
dues 523, 535, 538 and 542 of the Ja helix of
AsLOV2. The abilities of these proteins to bind SspB,
the cognate partner of SsrA, were compared by fluo-
rescence polarisation; whilst the sequence inserted at
538 showed the tightest binding affinity, insertion at
542 led to the greatest difference between light and dark
states. Proteins could be marked for light-dependent proteaso-
mal degradation by inserting a four-amino acid degrons, RRRG,
at residue 543 of AsLOV2.[21] A sequence from a cAMP-depen-
dent kinase inhibitor was inserted into the loop preceding the
AsLOV2 Ja, but this change led to inhibition of the target
enzyme even in the dark state.[29] In contrast, appending the
inhibitor sequence to the AsLOV2 Ja at residue 452 led to
light-dependent inhibition of the target kinase. Taken together,
these results suggest that only a rather narrow region of the
Ja region of AsLOV2 can be used to generate effective photo-
caged protein hybrids. This is emphasised by fusions of LOV to
Rac1, a GTPase, in which the addition or removal of single
amino acids drastically alters dark-state caging of the GTPase[30]
The key structural recognition element for proapoptotic pro-
teins is the Bcl homology 3 region (BH3), which binds as an a-
helix in a shallow groove found on the surface of Bcl family
proteins. BH3 recognition elements are much longer (21 resi-
dues rather than 7–9 residues, Table S1) than the sequences
that have previously been incorporated into the Ja helix of
AsLOV2, and hydrophobic side chains from four separate turns
contribute strongly to the binding affinity. In addition, several
intervening residues make highly conserved interactions or
dictate specificity for anti-apoptotic protein subfamilies.[31] We
chose the BH3 domain of BID, a broadly acting pro-apoptotic
protein, as a model sequence for changes to the Ja of AsLOV2.
Key residues of the Ja helix in AsLOV2 determine its dark-state
structure (Figure 1); G528A and N538E mutants show increased
helix docking in the dark state, whereas AsLOV2-I532E and
AsLOV2-A536E create “pseudo-light” mutants by compromising
Ja docking.[10,27] To design an efficient AsLOV2-based optoge-
netic tool that targets the heterodimers of the Bcl-2 family, the
hydrophobic character of residues I532, A536 and I539 of
AsLOV needed to be preserved, and D540, a residue that
makes an important electrostatic interaction to the core LOV
domain,[10] needed to be retained (Table 1).
Despite these compromises, a fluorescently labelled peptide
corresponding to the proposed Ja region of the hybrid LOV–
BID1 (Table 1) showed only a twofold reduction in affinity for
Bcl-xL (KD=462.6 nm) relative to the parent sequence
(Table S4). A plasmid containing DNA encoding AsLOV2 fused
to the C terminus of a domain used for affinity purification,
hisactophilin-C49S,[32] was used to construct hybrids between
AsLOV2 and BID BH3. Although wild-type Hisact-AsLOV2 re-
laxed with a half-life of approximately 1 min after photoactiva-
tion, a mutant with a different hydrophobic side chain near
the active site, Hisact-AsLOV2-V416I, had a significantly longer-
lived (t1=2=7.7 min) photoactivated state (Table S5).
[33–34] The hi-
sactophilin prosthetic domain was replaced by a His-tag, and
BH3-like sequences were added at different positions of the Ja
helix (Table 1) to generate LOV-BID1–4. Solutions of these hy-
brids were exposed to 455 nm light generated by an LED, and
the recovery of FMN absorbance at 455 nm was followed by
UV spectroscopy; the ellipticity change at 222 nm in the circu-
lar dichroism spectrum was measured by detecting the recov-
ery of a-helicity after exposure to blue light. All four proteins
were photoresponsive, and the half-lives obtained from CD
and UV measurements were broadly similar, varying between
10.4 (LOV-BID1) and 7.5 min (LOV-BID3; Table 1 and S5).
The thermal stabilities of the hybrids, as measured by CD
spectroscopy, decreased from LOV-BID1 to LOV-BID4 (Table 1).
The degree of structural change shown by CD spectroscopy
upon photoactivation is strongly reduced in LOV-BID1 com-
pared to AsLOV2-V416I (Figure 3). Comparison of the mean res-
idue ellipticities of photoactivated states of AsLOV2 (V416I)
and LOV-BID1 at 222 nm suggests a decreased helicity in the
dark state, as both the Ja helix in the light state of wild-type
AsLOV2[34] and BID BH3 peptides[22] are unstructured. LOV-BID2
shows little difference in structure between the dark and pho-
Table 1. Amino acid sequences of the Ja-helix sequences (BID BH3-type sequences
underlined, altered residues in italics). The LOV-BID peptide consists of the bold resi-
dues in LOV-BID1 with an additional A523C change to accommodate a fluorophore.
Protein[a] Partial sequence [Ja region] Tm t1=2
UV
[8C] [min]
His6-AsLOV2-
V416I
11.40.12
BID BH3
LOV-BID1 DAAEDIGVNIARHLAQVGDSIDRSIPDANLRPEDLWAN 66 10.40.05
LOV-BID2 DAAEREGVMLIKDIARNIDRALAEVGDSIDRSI 55 8.600.05
LOV-BID3 DAAEREGVMLIKKTADIIDNAARELAQVGDSIDRSI 51 7.500.17
LOV-BID4 DAAEREGVMLIKKTAENIDIARNIARHLAQVGDSIDRSI 49 7.800.75
[a] All LOV-BID proteins described include the V416I mutation to stabilise the cystein-
yl-FMN adduct.
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toactivated states, but single-wavelength monitoring could be
used to fit a decay curve to a change at 222 nm. As the value
obtained matches the half-life of the other hybrids, it appears
the Ja helix is either disordered in the dark state or maintains
helicity in the photoactivated state rather than cysteinyl-FMN
adduct formation becoming decoupled from structural
changes. Much larger changes were observed in the CD spec-
tra for light-activated and dark-state LOV-BID1, LOV-BID3 and
LOV-BID4 samples.
A fluorescence anisotropy assay was used to measure the
ability of the hybrids LOV-BID1–4 in their light-activated and
dark states to target fluorescently labelled loop-truncated Bcl-
xL.
[22–23] As expected, no binding was observed for AsLOV2
(V416I) either before or after photoactivation (Figure 4). LOV-
BID hybrids on the other hand, showed high-nanomolar affini-
ties for Bcl-xL in their photoactivated states. Light-state dissoci-
ation constants decreased as the length of hybrid Ja helix in-
creased (Table 2); this possibly reflects the increased accessibili-
ty of the BH3 motif. No binding to Bcl-xL could be measured in
the dark-adapted states of LOV-BID1, LOV-BID3 and LOV-BID4,
but LOV-BID2 bound to Bcl-xL in the dark with threefold re-
duced affinity compared to that in its photoactivated state.
This suggests that the Ja region of LOV-BID2 is poorly caged
in the dark state rather than remaining structured in the light-
activated state.
Figure 3. Circular dichroism spectra of proteins in the dark-adapted (blue) and lit states (red) after 30 s of irradiation with a 1 W 455 nm LED in sodium phos-
phate (50 mm, pH 7.5) buffer containing sodium chloride (10 mm). A) AsLOV2 (V416I) B) LOV-BID1 C) LOV-BID2 D) LOV-BID3 E) LOV-BID4.
Figure 4. Normalised fluorescent anisotropy binding curves of proteins to TAMRA-labelled Bcl-xL (S2C) (10 nm) in sodium phosphate buffer (50 mm, pH 7.5)
containing NaCl (10 mm) at 15 8C to minimise relaxation during the experiment in the dark-adapted (*) and lit states (*) after 30 s irradiation of with a 1 W,
455 nm LED A) AsLOV2 (V416I) ; B) LOV-BID1; C) LOV-BID2; D) LOV-BID3 and E) LOV-BID4.
ChemBioChem 2016, 17, 698 – 701 www.chembiochem.org Ó 2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim700
Communications
Without calculating the dark-state affinities, it is impossible
to calculate the dynamic range of LOV-BID1, LOV-BID3 and
LOV-BID4. However, the best dynamic range obtained in previ-
ous peptide experiments was a 23-fold difference in affinities
for an i,i+4 azobenzene-conjugated BID peptide.[22] An equiva-
lent dynamic range would equate to a dark state affinity of ap-
proximately 2 mm for LOV-BID4, which it greatly exceeds. Even
without further mutations, such as those used elsewhere to
modify the strength of Ja-helix docking, the switching magni-
tude of the LOV-BID proteins reported here is better than in
many previous reports[21,27–29] and similar to the best reported
values for LOV-SsrA variants optimized by phage display (36-
and 58-fold).[35] The penalty for embedding the BH3 sequence
closer to the core of the LOV domain is relatively low (~2.5-
fold) compared to LOV-SsrA proteins (~16-fold).[28] This might
reflect the structure of the binding site of the target protein;
Bcl-xL presents a shallow groove across one face with space at
either end for overhanging protein.
Incorporating Bid BH3-derived sequences into the Ja helix
of AsLOV2 did not alter the photochemistry of the LOV
domain; it was generally well tolerated, resulting in proteins
that underwent conformational changes in response to irradia-
tion with blue light. The affinity of the embedded BH3 sequen-
ces for Bcl-xL was dependent on the conformational state of
the LOV-BID fusions, which offer significant potential as opti-
cally controlled intracellular modulators of protein–protein in-
teractions. The relative ease of integration of peptide sequen-
ces based on amphiphilic helices (in contrast with previous
work incorporating more polar sequences) suggests wider
applications of LOV photoswitches to rapidly and reversibly
control protein levels and activities with light at the post-trans-
lational level. Photo-exposure of peptide epitopes in LOV
domain hybrids introduced into transiently or stably transfect-
ed cells will generate potent optogenetic tools that avoid the
difficulties of trafficking peptides across the cell membranes
and offer a complementary approach to the use of azobenzene
photoswitches.
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Table 2. Binding affinities of LOV proteins in their dark state and lit
states.
Protein Dark-adapted KD [nm] Light-activated state KD [nm]
AsLOV2 (V416I) n.d. n.d.
LOV-BID1 n.d. 21616
LOV-BID2 998111 27114
LOV-BID3 n.d. 1673
LOV-BID4 n.d. 895
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